Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02828397 · ClinicalTrials.gov registry record · Phase 1
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02828397 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT02828397, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
Interventions
- DRUG REGN2222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02828397
The ClinicalTrials.gov registry entry for NCT02828397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REGN2222 is the first listed.
NCT02828397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02828397 about?
NCT02828397 is a clinical study titled "Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects". Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
What is the current status of trial NCT02828397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-04. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02828397?
The interventions under investigation include: REGN2222 (DRUG).
Who is sponsoring clinical trial NCT02828397?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.